Clinical Trial

Cardioneuroablation for Bradyarrhythmia

Study acronym: CARDIOBOOST
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter prospective randomized blind controlled trial with a sham procedure group of the efficacy and safety of cardioneuroablation as a method of treating symptomatic bradycardia without a permanent pacemaker implantation
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-25; most recent amendment 2024-03-04.
Status change: Not Yet Recruiting → Recruiting 2024-03-04
Trial Details
NCT Number NCT06288633
Lead Sponsor Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Collaborators: Meshalkin National Medical Research Center, Ministry of Health of Russian Federation, The Federal Centre of Cardiovascular Surgery, Russia, Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare, City Clinical Hospital No.52 of Moscow Healthcare Department, National Medical Research Center for Therapy and Preventive Medicine, Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan, Tomsk National Research Medical Center of the Russian Academy of Sciences, Vishnevsky Center of Surgery, National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Conditions Bradycardia, Syncope, Sick Sinus Syndrome
Enrollment 106 participants
Start Date 2024-03-04
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-05